# Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors

> **NCT00720590** · NA · COMPLETED · sponsor: **Indiana University** · enrollment: 30 (actual)

## Conditions studied

- Endothelial Dysfunction

## Interventions

- **DRUG:** Atazanavir
- **DRUG:** Lopinavir/ritonavir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00720590
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-09
- **Final completion:** 2006-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720590, "Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00720590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*